Treatment Options for Agitation in Dementia
- 370 Downloads
Purpose of review
The goal of the current review is to provide an update on the management of agitation in persons with dementia with a focus on pharmacological management of persons with Alzheimer’s disease.
As consistently effective and safe pharmacologic interventions are still lacking, identifying and addressing medical and environmental precipitants remain a priority. Acetylcholinesterase inhibitors and memantine should be initiated to enhance cognition, and if present, management of insomnia or sundowning with trazodone is indicated. If agitation persists, treatment with citalopram can be initiated with attention paid to potential prolongation of the QT interval. Treatment with low doses of atypical antipsychotics such as risperidone or quetiapine can be effective after appropriate consideration of and disclosure of potential adverse effects.
In light of the lack of consistently effective treatments for agitation in dementia, there have been renewed efforts to define the condition and improve the design of trials of medications to treat it. Considering the heterogeneity of patients and their comorbidities as well as the specific nature of their “agitation”, there is no “one-size fits all” approach to agitation in AD. However, many options exist that can be prudently pursued for this common problem in this delicate population.
KeywordsAgitation Dementia Alzheimer’s disease Pharmacological Atypical antipsychotics, selective serotonin reuptake inhibitors
Preparation of this manuscript was supported by NIH P50 AG-005142.
Compliance with Ethical Standards
Conflict of Interest
John M. Ringman declares no potential conflict of interest. Lon Schneider reports grants from NIH and grants from the State of California, during the conduct of the study, and grants from NIH, grants and personal fees from Eli Lilly, grants and other from Lundbeck, grants and personal fees from Roche/Genentech, personal fees from Merck, personal fees from AC Immune, personal fees from Avraham, personal fees from Takeda, personal fees from Cognition, grants from Novartis, grants from Biogen, personal fees and other from vTv, personal fees and other from Allergan, personal fees from Neurim, personal fees from Axovant, personal fees from Neuronix, personal fees from Eisai, and personal fees from Toyama, outside the submitted work.
Human and animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.•• Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, et al. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015;27(1):7–17 In this review article, the expert panel of authors attempts to standardize the definition of agitation in dementia and its implementation in clinical studies.PubMedGoogle Scholar
- 5.Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatr Clin Neurosci. 2000;12(2):233–9.Google Scholar
- 8.• Salzman C, Jeste DV, Meyer RE, Cohen-Mansfield J, Cummings J, Grossberg GT, et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008;69(6):889–98 In this review article, the authors addressed potential underlying causes of the lack of consistent benefits for agitation in clinical trials, the adverse effects of atypical antipsychotics and the care with which they must be used in this context, and the need for safer and more effective treatments for agitation in dementia.PubMedPubMedCentralGoogle Scholar
- 11.Wolf D, Rhein C, Geschke K, Fellgiebel A. Preventable hospitalizations among older patients with cognitive impairments and dementia. Int Psychogeriatr. 2018:1–9.Google Scholar
- 12.Ihara ES, Tompkins CJ, Inoue M, Sonneman S. Results from a person-centered music intervention for individuals living with dementia. Geriatr Gerontol Int. 2018.Google Scholar
- 15.Romeo R, Zala D, Knapp M, Orrell M, Fossey J, Ballard C. Improving the quality of life of care home residents with dementia: cost-effectiveness of an optimized intervention for residents with clinically significant agitation in dementia. Alzheimers Dement. 2018.Google Scholar
- 19.Canevelli M, Valletta M, Trebbastoni A, Sarli G, D’Antonio F, Tariciotti L, et al. Sundowning in dementia: clinical relevance, pathophysiological determinants, and therapeutic approaches. Front Med (Lausanne). 2016;3:73.Google Scholar
- 21.Cummings JL, Koumaras B, Chen M, Mirski D, Rivastigmine Nursing Home Study T. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother. 2005;3(3):137–48.PubMedGoogle Scholar
- 29.Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;2:CD008191.Google Scholar
- 33.Finkel SI, Mintzer JE, Dysken M, Krishnan KR, Burt T, McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer’s disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19(1):9–18.PubMedGoogle Scholar
- 34.• Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. Jama. 2014;311(7):682–91 In this large controlled trial, a benefit of citalopram for agitation in AD was demonstrated, albeit with a risk of cardiotoxicity.PubMedPubMedCentralGoogle Scholar
- 39.•• Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525–38. This large randomized and controlled study was designed to mimic real-world prescribing practices and therefore the results are more easily generalizable.PubMedGoogle Scholar
- 41.Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, et al. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch Gen Psychiatry. 2007;64(11):1259–68.PubMedGoogle Scholar
- 44.Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007;15(11):918–31.PubMedGoogle Scholar
- 45.Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomized, placebo-controlled, double-blind study. Lancet Neurol. 2018;17(3):213–22.PubMedGoogle Scholar
- 46.Rabinovici GD, Carrillo MC, Forman M, DeSanti S, Miller DS, Kozauer N, et al. Multiple comorbid neuropathologies in the setting of Alzheimer’s disease neuropathology and implications for drug development. Alzheimers Dement (N Y). 2017;3(1):83–91.Google Scholar
- 50.Teng PR, Yeh CH, Lin CY, Lai TJ. Olanzapine-induced neuroleptic malignant syndrome in a patient with probable dementia with Lewy bodies. J Neuropsychiatr Clin Neurosci. 2012;24(4):E1–2.Google Scholar
- 54.Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuro-Psychopharmacol Biol Psychiatry. 2003;27(3):549–53.Google Scholar
- 64.• Brodaty H, Aerts L, Harrison F, Jessop T, Cations M, Chenoweth L, et al. Antipsychotic deprescription for older adults in long-term care: the HALT study. J Am Med Dir Assoc. 2018;19(7):592–600 e7. In this study, the authors demonstrated that it is frequently possible to discontinue atypical antipsychotics in agitated persons with dementia without relapse of symptoms.PubMedGoogle Scholar
- 67.Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019.Google Scholar
- 68.•• Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–734 In this comprehensive article, the authors review many practical dimensions of care of patients with AD, including management of agitation.PubMedGoogle Scholar